This early-stage study tests a new drug called furmonertinib in about 160 people with advanced or spreading non-small cell lung cancer that has certain gene changes (EGFR or HER2 mutations). The goal is to see if the drug is safe and can shrink tumors. Participants must have alre…
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC